Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Data Sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Public sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 Gene vector 360º synopsis, 2018 – 2032
2.2 Business trends
2.3 Vector type trends
2.4 Application trends
2.5 Disease trends
2.6 End user trends
Chapter 3 Gene Vector Market Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases
3.2.1.2 Development of more advanced gene editing technologies
3.2.1.3 Increasing demand for personalized medicine
3.2.1.4 Increase in R&D investments for the development of gene therapy
3.2.1.5 Ongoing research into viral vector-based gene therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of gene therapies
3.2.2.2 Challenges associated with regulatory approval of gene vectors development
3.3 Growth potential analysis
3.3.1 By vector type
3.3.2 By application
3.3.3 By disease
3.3.4 By end user
3.4 COVID- 19 impact analysis
3.5 Technological analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Market share analysis , 2022
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Gene Vector Market Size and Forecast, By Vector Type (USD Million)
5.1 Key trends, by vector type
5.2 Plasmid DNA
5.3 Retroviral
5.4 Lentiviral
5.5 Adenoviral
5.6 Adeno-associated viral
5.7 Other vector types
Chapter 6 Gene Vector Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Gene therapy
6.3 Vaccinology
6.4 Other applications
Chapter 7 Gene Vector Market Size and Forecast, By Disease (USD Million)
7.1 Key trends, by disease
7.2 Oncology
7.3 Genetic disorders
7.4 Infectious diseases
7.5 Other diseases
Chapter 8 Gene Vector Market Size and Forecast, By End-user (USD Million)
8.1 Key trends, by end-user
8.2 CDMOs
8.3 Pharmaceutical and biotechnology companies
8.4 Research institutes
8.5 CROs
Chapter 9 Gene Vector Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia and New Zealand
9.4.5 Rest of Asia pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Lonza
10.2 Merck KGaA
10.3 Thermo Fisher Scientific Inc.
10.4 Oxford Biomedica
10.5 Cobra Biologics
10.6 Novasep
10.7 Spark Therapeutics
10.8 Kaneka Eurogentec
10.9 Finvector Vision Therapies
10.10 Brammer Bio
10.11 Cell and Gene Therapy Catapult
10.12 FUJIFILM Diosynth Biotechnologies
10.13 uniQure N.V.
